logo
Plus   Neg
Share
Email

Stock Alert: Fly Leasing Climbs 20%

Shares of Fly Leasing Ltd. (FLY) are gaining more than 20 percent or $1.64 in Wednesday's morning trade at $9.79 despite no stock-specific news. The stock has traded in a range of $3.41 to $23.21 in the past 52 weeks.

U.S. stocks are rising on Wednesday amid continued optimism about the reopening of the economy. Airline and related stocks surged on Tuesday as they are expected to benefit from a pick up in travel demand when economic activity returns to normal.

Ireland-based Fly Leasing, through its subsidiaries, purchases and leases commercial aircraft under multi-year contracts to various airlines worldwide.

In early May, Fly Leasing reported first-quarter net income of $38.1 million or $1.24 per share, down from $45.0 million or $1.38 per share in the year-ago period. Adjusted earnings were $1.42, compared to $1.44 per share last year. Total revenues for the quarter declined to $121.56 million from $134.70 million a year ago.

At that time, Fly Leasing said it does not have any orders with the aircraft manufacturers and also has no near-term refinancing requirements.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Shares of Volkswagen Group were gaining around 3 percent in German trading after the automotive giant Thursday reported market recovery in the third quarter with improved deliveries in the month of September. For the first nine months of fiscal 2020, the company, meanwhile reported sharply lower earnings with weak revenues and sales volume. Comcast Corp. on Thursday reported a 37 percent decline in profit for the third quarter from last year, hurt primarily by revenue decline at NBCUniversal. Both adjusted earnings per share and quarterly revenues topped analysts' expectations. The company also declared a quarterly dividend. In the pre-market trade, CMCSA is trading at $42.83, up $0.85 or 2.02 percent. Regeneron announced positive results from its late stage COVID-19 outpatient trial, indicating that its antibody cocktail therapy significantly reduced virus levels and need for further medical attention. The trial results showed that investigational antibody cocktail, REGN-COV2, met the primary and key secondary endpoints.
Follow RTT